Clinical Report: Serum Levels of Interleukin-6 as a Neuroinflammatory Indicator

Overview

This study investigates serum IL-6 levels across various neurological disorders, revealing significant heterogeneity and potential as a diagnostic biomarker. Elevated IL-6 levels were particularly noted in traumatic brain injury, metabolic/toxic encephalopathy, and hemorrhagic stroke.

Background

Neurological disorders often present with overlapping symptoms, complicating accurate diagnosis. Identifying reliable biomarkers like IL-6 could enhance differential diagnosis and improve patient management. This study provides a comprehensive analysis of IL-6 levels across multiple neurological conditions, addressing a critical gap in current clinical practice.

Data Highlights

Key Findings

• Significant heterogeneity in serum IL-6 levels across 10 neurological disorders (p < 0.001).
• Highest IL-6 levels observed in traumatic brain injury, metabolic/toxic encephalopathy, and hemorrhagic stroke.
• Age and sex were identified as independent predictors of IL-6 levels.
• IL-6 demonstrated good diagnostic performance for distinguishing acute brain injuries from healthy status.
• Limited discriminatory power for differentiating between various neurological diseases.

Clinical Implications

Serum IL-6 levels can serve as a valuable biomarker for screening acute neurological conditions, particularly in emergency settings. Clinicians should consider age- and sex-stratified reference intervals for accurate interpretation of IL-6 results.

Conclusion

This study underscores the potential of serum IL-6 as a neuroinflammatory biomarker for acute brain injury, warranting further validation in diverse clinical settings.

References

1. Frontiers in Immunology, 2026 -- Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus
2. Frontiers in Immunology, 2026 -- Serum and cerebrospinal fluid neuroinflammatory biomarkers and trimethylamine N-oxide: associations with white matter lesion severity
3. Brain, 2026 -- Association of Blood Inflammation with Neuroinflammation and Prognosis in Frontotemporal Lobar Degeneration
4. Frontiers in Immunology, 2026 -- Serum inflammatory cytokines in the progression of depression
5. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial - PMC
6. The Role of IL-6 in Ischemic Stroke | MDPI
7. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial - PMC
8. The Role of IL-6 in Ischemic Stroke | MDPI